Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

As the tumors grew, the researchers observed fewer T cells and a reduction in cytokine levels, including interleukin-3 (IL-3), hallmarks of T cell exhaustion. Treating the tumor-bearing mice with IL-3 ...